Zimmer valuation not reflecting Biomet deal potential, says Cantor Cantor says Zimmer remains its preferred name in orthopedics despite its "disappointing" Q2 report, as the firm believes the stock's valuation doesn't properly reflects the potential from its tie-up with Biomet. Cantor thinks Zimmer management's synergy targets are possibly conservative and raised its price target on the stock to $117 from $113.
BIOLASE CEO Jeffrey Nugent to step down, Harold Flynn appointed CEO BIOLASE (BIOL) announced that Harold Flynn Jr. will become president and CEO, effective July 13. The current president and CEO Jeffrey Nugent will step down at that time. Since 2007, Flynn has been president of Zimmer Dental, a manufacturer and provider of medical devices for the dental market. Zimmer Dental is a division of Zimmer Holdings (ZMH).